Himalaya Nutravedics India
Minimum investment
Employee
₹—
HNI
—
Retail application
₹1,20,000
IPO open date
22 Sept
IPO close date
24 Sept
Allotment date
28 Sept
Funds unblock or debit
28 Sept
Tentative listing date
29 Sept
Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. Its product portfolio includes classical Ayurvedic formulations based on recognised Ayurvedic texts, proprietary Ayurvedic formulations and nutraceutical supplements. The products are available in dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. Its nutraceutical products include formulations using vitamins, minerals, herbal extracts, amino acids and other permitted ingredients. The company operates through both its own-brand and third-party manufacturing businesses. It commenced manufacturing operations in September 2022 from its facility in Cherlapally, Hyderabad, Telangana. The company has a stockist-driven distribution network across multiple states in India and an on-ground sales and marketing team of approximately 56 personnel, including regional managers and medical representatives. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Funding capital expenditure requirements — Rs 13.75 crore Investment in branding, digital marketing, and sales expansion — Rs 7.50 crore General corporate purposes.
All values are in ₹ Cr
14.42
FY24
21
FY25
43.07
FY26
- The company claims to operate an integrated manufacturing facility capable of producing medicated oils, soft gelatin capsules, hard gelatin capsules, tablets and liquid orals. This allows it to manufacture products across multiple dosage forms for its Ayurvedic and nutraceutical businesses.
- Since commencing manufacturing operations in September 2022, the company has established a presence across multiple states in India. It has built a stockist-driven distribution network supported by an on-ground sales and marketing team.
- The company offers classical Ayurvedic formulations, proprietary Ayurvedic formulations, and nutraceutical supplements across areas such as gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, infertility, and general wellness.
- The company operates through both its own-brand business and third-party manufacturing operations. This model allows it to manufacture and market its own formulations while also undertaking contract manufacturing for other Ayurvedic and nutraceutical companies.
- The company claims that its products have received repeat prescriptions and re-orders from healthcare practitioners while relying on scientific detailing, continuing medical education programmes, medical camps, and practitioner engagement rather than mass media advertising.
- In FY26, the company’s own-brand business, comprising classical Ayurvedic formulations, proprietary Ayurvedic formulations, and nutraceutical supplements, contributed approximately Rs 22.02 crore, representing 51.14% of its total revenue.
- The company has shown a consistent increase in revenue from operations and profit after tax. Revenue from operations increased from Rs 14.42 crore to Rs 21.00 crore and Rs 43.07 crore in FY24, FY25, and FY26, respectively. PAT also increased from Rs 0.43 crore to Rs 2.23 crore and then Rs 7.39 crore during the same period.
FAQs
What is the issue size of Himalaya Nutravedics India IPO?
The issue size is ₹26 Cr.
What is the price band of Himalaya Nutravedics India IPO?
The price band is ₹100 to ₹106 per share.
What is the GMP of Himalaya Nutravedics India today?
The latest GMP is ₹0.
What is the subscription status of Himalaya Nutravedics India?
The latest available subscription figures are Overall 0.44x.
What are the open and close dates of Himalaya Nutravedics India IPO?
The IPO opens on 22 Sept 2026 and closes on 24 Sept 2026.
What is the allotment chance of Himalaya Nutravedics India IPO?
Allotment chance is not available because retail subscription data is not available.
What is the lot size of Himalaya Nutravedics India IPO?
The lot size is 1,200 shares.
Who is the registrar of Himalaya Nutravedics India IPO?
KFIN TECHNOLOGIES LIMITED
GMP Today
•Est. premium
₹0
0.0%
Allotment Chance
i—
Based on retail subscription
Himalaya Nutravedics India IPO
Himalaya Nutravedics India
₹1,20,000/ 1,200 shares
Minimum investment
IPO details
IPO details
Minimum investment
₹1,20,000
Price range
₹100 - ₹106
Lot size
1,200
Issue size
₹26 Cr
IPO document
RHP PDF
Subscription rate
Subscription rate
Application Details
Schedule
Schedule
IPO open date
22 Sept 2026
IPO close date
24 Sept 2026
Allotment date
28 Sept 2026
Funds unblock or debit
28 Sept 2026
Tentative listing date
29 Sept 2026
About
About
Industry
—
Registrar
KFIN TECHNOLOGIES LIMITED
Lead Manager
—
Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. Its product portfolio includes classical Ayurvedic formulations based on recognised Ayurvedic texts, proprietary Ayurvedic formulations and nutraceutical supplements. The products are available in dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. Its nutraceutical products include formulations using vitamins, minerals, herbal extracts, amino acids and other permitted ingredients. The company operates through both its own-brand and third-party manufacturing businesses. It commenced manufacturing operations in September 2022 from its facility in Cherlapally, Hyderabad, Telangana. The company has a stockist-driven distribution network across multiple states in India and an on-ground sales and marketing team of approximately 56 personnel, including regional managers and medical representatives. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Funding capital expenditure requirements — Rs 13.75 crore Investment in branding, digital marketing, and sales expansion — Rs 7.50 crore General corporate purposes.
Financials
Financials
All values are in ₹ Cr
14.42
FY24
21
FY25
43.07
FY26
Pros & Cons
- The company claims to operate an integrated manufacturing facility capable of producing medicated oils, soft gelatin capsules, hard gelatin capsules, tablets and liquid orals. This allows it to manufacture products across multiple dosage forms for its Ayurvedic and nutraceutical businesses.
- Since commencing manufacturing operations in September 2022, the company has established a presence across multiple states in India. It has built a stockist-driven distribution network supported by an on-ground sales and marketing team.
- The company offers classical Ayurvedic formulations, proprietary Ayurvedic formulations, and nutraceutical supplements across areas such as gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, infertility, and general wellness.
- The company operates through both its own-brand business and third-party manufacturing operations. This model allows it to manufacture and market its own formulations while also undertaking contract manufacturing for other Ayurvedic and nutraceutical companies.
- The company claims that its products have received repeat prescriptions and re-orders from healthcare practitioners while relying on scientific detailing, continuing medical education programmes, medical camps, and practitioner engagement rather than mass media advertising.
- In FY26, the company’s own-brand business, comprising classical Ayurvedic formulations, proprietary Ayurvedic formulations, and nutraceutical supplements, contributed approximately Rs 22.02 crore, representing 51.14% of its total revenue.
- The company has shown a consistent increase in revenue from operations and profit after tax. Revenue from operations increased from Rs 14.42 crore to Rs 21.00 crore and Rs 43.07 crore in FY24, FY25, and FY26, respectively. PAT also increased from Rs 0.43 crore to Rs 2.23 crore and then Rs 7.39 crore during the same period.
Frequently Asked Questions
What is the issue size of Himalaya Nutravedics India IPO?
The issue size is ₹26 Cr.
What is the price band of Himalaya Nutravedics India IPO?
The price band is ₹100 to ₹106 per share.
What is the GMP of Himalaya Nutravedics India today?
The latest GMP is ₹0.
What is the subscription status of Himalaya Nutravedics India?
The latest available subscription figures are Overall 0.44x.
What are the open and close dates of Himalaya Nutravedics India IPO?
The IPO opens on 22 Sept 2026 and closes on 24 Sept 2026.
What is the allotment chance of Himalaya Nutravedics India IPO?
Allotment chance is not available because retail subscription data is not available.
What is the lot size of Himalaya Nutravedics India IPO?
The lot size is 1,200 shares.
Who is the registrar of Himalaya Nutravedics India IPO?
KFIN TECHNOLOGIES LIMITED
GMP Today
₹0
Estimated Premium
0.0%
Allotment Chance
—